Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T, Kamataki T, Kawamura J, Yatani R, Shiraishi T
Second Department of Pathology, Mie University School of Medicine, 2-174 Edobashi, Tsu, 514, Mie, Japan.
Cancer Lett. 2001 Apr 26;165(2):171-7. doi: 10.1016/s0304-3835(01)00398-6.
Associations between genetic polymorphisms of CYP1A1, CYP1A2, CYP2E1, GSTM1 and GSTT1 and prostate cancer (PCa) were analyzed in a case-control study of 315 individuals. The frequency of valine (Val)/valine (Val) genotypes for CYP1A1 was 11.3% in cases compared with 5.5% in controls, this polymorphism thus being associated with a significantly increased risk of PCa (odds ratio=2.4, 95% confidence interval (CI)=1.01-5.57). No links were detected between PCa and polymorphisms in other enzymes. However, the combination of CYP1A1 (Ile/Val and/or Val/Val) polymorphisms with the GSTM1 null type resulted in an OR of 2.2 (CI=1.10-4.57, 1.12-4.20, respectively). This study suggests that the CYP1A1 polymorphism and its combination with GSTM1 may be associated with PCa susceptibility in the Japanese population.
在一项针对315名个体的病例对照研究中,分析了细胞色素P450 1A1(CYP1A1)、细胞色素P450 1A2(CYP1A2)、细胞色素P450 2E1(CYP2E1)、谷胱甘肽S-转移酶M1(GSTM1)和谷胱甘肽S-转移酶T1(GSTT1)的基因多态性与前列腺癌(PCa)之间的关联。CYP1A1的缬氨酸(Val)/缬氨酸(Val)基因型在病例组中的频率为11.3%,而在对照组中为5.5%,因此这种多态性与PCa风险显著增加相关(优势比=2.4,95%置信区间(CI)=1.01-5.57)。未检测到PCa与其他酶的多态性之间存在关联。然而,CYP1A1(异亮氨酸/缬氨酸(Ile/Val)和/或缬氨酸/缬氨酸(Val/Val))多态性与GSTM1无效型的组合导致优势比分别为2.2(CI=1.10-4.57,1.12-4.20)。这项研究表明,CYP1A1多态性及其与GSTM1的组合可能与日本人群的PCa易感性相关。